# A Single Center, Prospective Clinical Trial of Intravenous Ertapenem in the Treatment of Hurley Stage II or III Hidradenitis Suppurativa

> **NCT05255575** · — · WITHDRAWN · sponsor: **Henry Ford Health System**

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** Ertapenem

## Key facts

- **NCT ID:** NCT05255575
- **Lead sponsor:** Henry Ford Health System
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-03-01
- **Primary completion:** 2019-07-07
- **Final completion:** 2019-08-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** unavailable staff to support project
- **Last updated:** 2022-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05255575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05255575, "A Single Center, Prospective Clinical Trial of Intravenous Ertapenem in the Treatment of Hurley Stage II or III Hidradenitis Suppurativa". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05255575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*